PL2643698T3 - Biomarkery do przewidywania skuteczności immunoterapii raka - Google Patents
Biomarkery do przewidywania skuteczności immunoterapii rakaInfo
- Publication number
- PL2643698T3 PL2643698T3 PL11788121.9T PL11788121T PL2643698T3 PL 2643698 T3 PL2643698 T3 PL 2643698T3 PL 11788121 T PL11788121 T PL 11788121T PL 2643698 T3 PL2643698 T3 PL 2643698T3
- Authority
- PL
- Poland
- Prior art keywords
- biomarkers
- predicting
- efficacy
- against cancer
- immunotherapy against
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000000090 biomarker Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41698110P | 2010-11-24 | 2010-11-24 | |
| GBGB1021289.2A GB201021289D0 (en) | 2010-12-15 | 2010-12-15 | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
| US42365210P | 2010-12-16 | 2010-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2643698T3 true PL2643698T3 (pl) | 2016-12-30 |
Family
ID=43567254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11788121.9T PL2643698T3 (pl) | 2010-11-24 | 2011-11-22 | Biomarkery do przewidywania skuteczności immunoterapii raka |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8669063B2 (pl) |
| EP (1) | EP2643698B1 (pl) |
| JP (1) | JP6005051B2 (pl) |
| KR (1) | KR20130119453A (pl) |
| CN (1) | CN103384827B (pl) |
| AU (1) | AU2011333819A1 (pl) |
| BR (1) | BR112013012820A2 (pl) |
| CA (1) | CA2818738A1 (pl) |
| EA (1) | EA201390762A1 (pl) |
| ES (1) | ES2592957T3 (pl) |
| GB (1) | GB201021289D0 (pl) |
| HU (1) | HUE030005T2 (pl) |
| MX (1) | MX341734B (pl) |
| NZ (1) | NZ609712A (pl) |
| PL (1) | PL2643698T3 (pl) |
| SG (1) | SG190698A1 (pl) |
| WO (1) | WO2012069462A1 (pl) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2172211T3 (en) | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US9026531B2 (en) * | 2012-04-17 | 2015-05-05 | Cerner Innovation, Inc. | Associating multiple data sources into a web-accessible framework |
| WO2014003853A1 (en) | 2012-06-26 | 2014-01-03 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| CN103048453B (zh) * | 2012-12-18 | 2014-11-26 | 苏州浩欧博生物医药有限公司 | 一种糖类抗原ca19-9的纳米磁微粒化学发光测定试剂盒及其制备方法和检测方法 |
| CA2928271C (en) | 2013-11-07 | 2022-05-31 | Medial Research Ltd. | Methods and systems of evaluating a risk of lung cancer |
| EP2942629A1 (en) * | 2014-05-08 | 2015-11-11 | Universität Würzburg | Predictive markers for successful cancer immunotherapy |
| GB201505585D0 (en) * | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| WO2017008046A1 (en) * | 2015-07-08 | 2017-01-12 | Children's Hospital Medical Center | Loss of transcriptional fidelity leads to immunotherapy resistance in cancers |
| CN108027373B (zh) | 2015-07-13 | 2021-04-09 | 佰欧迪塞克斯公司 | 受益于阻断t细胞程序性细胞死亡1(pd-1)检查点蛋白的配体活化的抗体药物的黑素瘤患者的预测性测试和分类器开发方法 |
| US20170199961A1 (en) | 2015-12-16 | 2017-07-13 | Gritstone Oncology, Inc. | Neoantigen Identification, Manufacture, and Use |
| US11710539B2 (en) | 2016-02-01 | 2023-07-25 | Biodesix, Inc. | Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy |
| CN105624110A (zh) * | 2016-02-29 | 2016-06-01 | 时宏珍 | Hla-a0201限制性抗psa抗原特异性ctl的制备方法 |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| KR102245021B1 (ko) * | 2016-05-09 | 2021-04-26 | 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) | 고형 암을 갖는 환자의 분류 방법 |
| US20190177430A1 (en) * | 2016-08-24 | 2019-06-13 | The Wistar Institute Of Anatomy And Biology | Methods of Treating Cancers With Chemotherapy With Reduced Toxicity |
| CN106198987A (zh) * | 2016-08-31 | 2016-12-07 | 辽宁迈迪生物科技股份有限公司 | 一种用于评价肿瘤免疫细胞疗法的检测标记物及其检测方法和应用 |
| KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP3566054A4 (en) * | 2017-01-05 | 2020-12-09 | Biodesix, Inc. | PROCESS FOR IDENTIFYING CANCER PATIENTS LIKELY TO BENEFIT FROM IMMUNOTHERAPY FOR LASTING SUSTAINABLE SUB-GROUPS OF PATIENTS WHO HAVE A BAD PROGNOSIS GENERALLY |
| US11747345B2 (en) | 2017-02-21 | 2023-09-05 | The Board Of Regents Of The University Of Texas System | Prediction and treatment of immunotherapeutic toxicity |
| US10699007B2 (en) * | 2017-03-13 | 2020-06-30 | Oracle International Corporation | Hybrid univariate/multivariate prognostic-surveillance technique |
| CN110023760B (zh) * | 2017-06-02 | 2023-04-14 | 李宗均 | 一种利用结直肠癌患者和正常人外周血内免疫细胞的分布差异评估免疫力并提供结直肠癌发病情况信息的诊断工具 |
| CN118888004A (zh) | 2017-10-10 | 2024-11-01 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
| CN112105381A (zh) | 2018-03-29 | 2020-12-18 | 佰欧迪塞克斯公司 | 用于识别癌症患者的原发性免疫抗性的设备和方法 |
| US20210263045A1 (en) * | 2018-04-06 | 2021-08-26 | The Board Of Regents Of The University Of Texas System | Prediction and treatment of immunotherapeutic toxicity |
| CN108624650B (zh) * | 2018-05-14 | 2022-04-29 | 乐普（北京）医疗器械股份有限公司 | 判断实体瘤是否适合免疫治疗的方法和检测试剂盒 |
| CN110885886B (zh) * | 2018-09-07 | 2023-04-07 | 华中科技大学同济医学院附属协和医院 | 一种胶质母细胞瘤鉴别诊断及胶质瘤生存预后的分型方法 |
| KR102159538B1 (ko) * | 2019-01-11 | 2020-09-24 | 충남대학교 산학협력단 | 폐암 환자의 면역항암제에 대한 치료 반응성 예측용 il-6 마커 및 이의 용도 |
| US11216742B2 (en) | 2019-03-04 | 2022-01-04 | Iocurrents, Inc. | Data compression and communication using machine learning |
| US20220165362A1 (en) * | 2019-03-28 | 2022-05-26 | Hoffmann-La Roche Inc. | Cancer prognosis |
| CN111257563B (zh) * | 2020-01-22 | 2022-08-23 | 广州泛恩生物科技有限公司 | Cxcl13检测剂在制备预测免疫治疗效果的试剂盒中的用途 |
| IL299323A (en) * | 2020-06-21 | 2023-02-01 | Oncohost Ltd | Host signatures for predicting immunotherapy response |
| WO2022006514A1 (en) * | 2020-07-02 | 2022-01-06 | Gopath Laboratories Llc | Immune profiling and methods of using same to predict responsiveness to an immunotherapy and treat cancer |
| CN115777065A (zh) * | 2020-07-10 | 2023-03-10 | 积水医疗株式会社 | 含有tarc的组合物和用于改善tarc的储存稳定性的方法 |
| CN113219173A (zh) * | 2021-05-11 | 2021-08-06 | 中南大学湘雅医院 | Sh2b1在肺癌诊断中的应用 |
| CN113462776B (zh) * | 2021-06-25 | 2023-03-28 | 复旦大学附属肿瘤医院 | m6A修饰相关联合基因组在预测肾透明细胞癌患者免疫治疗疗效中的应用 |
| CN115058440B (zh) * | 2022-06-08 | 2023-08-15 | 郑州轻工业大学 | 催化合成天然蔗糖酯的工程菌及其构建方法和应用 |
| CN115612737A (zh) * | 2022-08-03 | 2023-01-17 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | 一种胃癌免疫治疗疗效预测和预后评估的方法及其应用 |
| CN118072954A (zh) * | 2024-02-06 | 2024-05-24 | 江南大学附属医院 | 一种基于trp评分系统的胃癌免疫治疗反应预测方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| JP3490893B2 (ja) * | 1998-06-02 | 2004-01-26 | 富士レビオ株式会社 | 胃癌の診断方法 |
| WO2005098446A2 (en) * | 2004-03-31 | 2005-10-20 | The Johns Hopkins University | Biomarkers for ovarian cancer |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| CA2628091A1 (en) * | 2005-11-02 | 2007-05-18 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
| US20090035801A1 (en) * | 2005-12-27 | 2009-02-05 | Power3 Medical Products, Inc. | Twelve (12) protein biomarkers for diagnosis and early detection of breast cancer |
| ATE476657T1 (de) * | 2006-04-24 | 2010-08-15 | Critical Care Diagnostics Inc | Vorhersage von letalität und detektion von schweren erkrankungen |
| AT504231A1 (de) * | 2006-10-03 | 2008-04-15 | Hans Dr Loibner | Prädiktive parameter |
| UA103882C2 (uk) * | 2007-07-27 | 2013-12-10 | Імматікс Біотекнолоджіс Гмбх | Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина |
| GB0718167D0 (en) * | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| EP2080812A1 (en) * | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
| EP2105740A1 (en) * | 2008-03-28 | 2009-09-30 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Biomarkers for monitoring or predicting the treatment of cancer |
| EP2304631A1 (en) | 2008-06-16 | 2011-04-06 | Sividon Diagnostics GmbH | Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer |
| WO2010076322A1 (en) | 2008-12-30 | 2010-07-08 | Siemens Healthcare Diagnostics Inc. | Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer |
| US20100240546A1 (en) * | 2009-03-20 | 2010-09-23 | Samuel Chun Lap Lo | Use of biomarkers for the diagnosis and prognosis of lung cancer |
-
2010
- 2010-12-15 GB GBGB1021289.2A patent/GB201021289D0/en not_active Ceased
-
2011
- 2011-11-22 HU HUE11788121A patent/HUE030005T2/en unknown
- 2011-11-22 ES ES11788121.9T patent/ES2592957T3/es active Active
- 2011-11-22 BR BR112013012820A patent/BR112013012820A2/pt active Search and Examination
- 2011-11-22 JP JP2013540324A patent/JP6005051B2/ja not_active Expired - Fee Related
- 2011-11-22 PL PL11788121.9T patent/PL2643698T3/pl unknown
- 2011-11-22 MX MX2013005762A patent/MX341734B/es active IP Right Grant
- 2011-11-22 SG SG2013035530A patent/SG190698A1/en unknown
- 2011-11-22 US US13/302,674 patent/US8669063B2/en active Active
- 2011-11-22 CN CN201180056555.2A patent/CN103384827B/zh not_active Expired - Fee Related
- 2011-11-22 AU AU2011333819A patent/AU2011333819A1/en not_active Abandoned
- 2011-11-22 EA EA201390762A patent/EA201390762A1/ru unknown
- 2011-11-22 NZ NZ609712A patent/NZ609712A/en not_active IP Right Cessation
- 2011-11-22 WO PCT/EP2011/070661 patent/WO2012069462A1/en not_active Ceased
- 2011-11-22 KR KR1020137015847A patent/KR20130119453A/ko not_active Ceased
- 2011-11-22 CA CA2818738A patent/CA2818738A1/en not_active Abandoned
- 2011-11-22 EP EP11788121.9A patent/EP2643698B1/en active Active
-
2014
- 2014-01-17 US US14/158,054 patent/US9389235B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6005051B2 (ja) | 2016-10-12 |
| AU2011333819A1 (en) | 2013-05-23 |
| EP2643698A1 (en) | 2013-10-02 |
| US20140234347A1 (en) | 2014-08-21 |
| NZ609712A (en) | 2015-05-29 |
| US9389235B2 (en) | 2016-07-12 |
| MX2013005762A (es) | 2013-08-12 |
| WO2012069462A1 (en) | 2012-05-31 |
| EA201390762A1 (ru) | 2013-09-30 |
| HUE030005T2 (en) | 2017-04-28 |
| MX341734B (es) | 2016-08-31 |
| US8669063B2 (en) | 2014-03-11 |
| KR20130119453A (ko) | 2013-10-31 |
| CN103384827B (zh) | 2016-06-08 |
| EP2643698B1 (en) | 2016-06-22 |
| CA2818738A1 (en) | 2012-05-31 |
| GB201021289D0 (en) | 2011-01-26 |
| JP2014500493A (ja) | 2014-01-09 |
| ES2592957T3 (es) | 2016-12-02 |
| BR112013012820A2 (pt) | 2017-05-09 |
| CN103384827A (zh) | 2013-11-06 |
| SG190698A1 (en) | 2013-07-31 |
| US20120128702A1 (en) | 2012-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2643698T3 (pl) | Biomarkery do przewidywania skuteczności immunoterapii raka | |
| IL221719A (en) | Biomarkers for Ternostics | |
| WO2012012225A9 (en) | Predicting cancer outcome | |
| SG10201710447QA (en) | Pancreatic cancer biomarkers and uses thereof | |
| EP2788763A4 (en) | BIOMARKERS FOR RENAL CANCER AND METHODS OF USE | |
| HUE056926T2 (hu) | Új síkbeli predikciós mód | |
| WO2011163332A9 (en) | Methods for detecting cancer | |
| GB201016139D0 (en) | Cancer phosholipidome | |
| GB201021482D0 (en) | Improved downlights | |
| ZA201703026B (en) | Biomarkers for the prediction of incident cancer | |
| GB201021502D0 (en) | Biomarkers | |
| GB201012590D0 (en) | Methods for diagnosing cancer | |
| GB201008340D0 (en) | Biomarkers | |
| GB201018056D0 (en) | Biomarkers | |
| GB201120860D0 (en) | Cancer immunotherapy | |
| WO2012167112A9 (en) | Gastric cancer biomarkers | |
| GB201004442D0 (en) | Biomarker | |
| EP2707721A4 (en) | BIOMARKERS PREDICTIVE FOR PROSTATE CANCER | |
| GB201005561D0 (en) | Biomarkers | |
| GB201001444D0 (en) | Biomarkers | |
| GB2510539B (en) | Biomarkers of cancer | |
| GB201010316D0 (en) | Biomarkers | |
| EP2501845A4 (en) | KREBSBIOMARKER | |
| GB201004304D0 (en) | Biomarkers for prostate cancer | |
| EP2649225A4 (en) | BIOMARKERS FOR THE PREDICTION OF BREAST CANCER |